Protocols
26 protocol(s) meet the specified criteria
Disease Site: Other
Protocol No.TitleStatus
11-1474AAccountability for Cancer Care through Undoing Racism and Equity (ACCURE)Open
13-2058Internet Tobacco Vendors Youth Purchase SurveyOpen
15-3137 A Feasibility Study of Antineoplastic Drug Exposure among Nursing AssistantsOpen
17-1493Expanded Access of Neratinib for Use with Capecitabine in Patients with Metastatic Breast Cancer and CNS MetastasisOpen (affiliates only)
A031102-CIRBA Randomized Phase III Trial Comparing Conventional-Dose Chemotherapy Using Paclitaxel, Ifosfamide, and Cisplatin (Tip) With High-Dose Chemotherapy Using Mobilizing Paclitaxel Plus Ifosfamide Followed By High-Dose Carboplatin And Etoposide (Ti-Ce) As First Salvage Treatment in Relapsed or Refractory Germ Cell Tumors Open
AALL0331Standard Risk B-precursor Acute Lymphoblastic LeukemiaOpen
AMGEN359A Randomized, Double-Blind, Placebo-Controlled, Multi-Center Phase 3 Study of Denosumab as Adjuvant Treatment for Women with Early-Stage Breast Cancer at High Risk of Recurrence (D-CARE)Open (affiliates only)
AMGEN482A Randomized, Double-Blind, Multicenter Study of Denosumab Compared With Zoledronic Acid in the Treatment of Bone Disease in Subjects With Newly Diagnosed Multiple MyelomaOpen (affiliates only)
ASG-22CE-13-2A Phase 1 Study of the Safety and Pharmacokinetics of Escalating Doses of ASG-22CE Given as Monotherapy in Subjects with Metastatic Urothelial Cancer and Other Malignant Solid Tumors that Express Nectin-4Open
C16-170Prostate Cancer Outcomes: An International Registry to Improve Outcomes in Men with Advanced Prostate Cancer (IRONMAN)Open
DELETETEST4A four part, Phase I Dose-Escalation Study of the Combinations of Concurrent BKM120 and Capecitabine,or Concurrent BKM120 and Capecitabine and Trastuzumab, in Patients with Metastatic Colon Cancer (Test4)Open
ETCTN9767-CIRBAn Open Label, Multicenter, Single arm Phase II study to evaluate the Activity and Tolerability of the novel mTOR Inhibitor, MLN0128 (TAK-228), in patients with Locally Advanced or Metastatic Transitional Cell Carcinoma of the urothelial tract whose tumors harbor a TSC1 and/or a TSC2 mutation.Open
GOG-3012A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Multicenter Study of Niraparib Maintenance Treatment in Patients with HRD- Positive Advanced Ovarian Cancer Following Response on Front-Line Platinum-Based ChemotherapyOpen
J1651Phase 2 Study of Azacitidine (AZA) in Combination with Pembrolizumab in Relapsed/Refractory Acute Myeloid Leukemia (AML) Patients and in Newly Diagnosed Older (>65 Years) AML PatientsOpen
KCP-330-012STORMA Phase 2b, Open-Label, Single-Arm Study of Selinexor (KPT-330) Plus Low-Dose Dexamethasone in Patients with Multiple Myeloma Previously Treated with Lenalidomide, Pomalidomide, Bortezomib, Carfilzomib, and an anti-CD38 Monoclonal Antibody (mAb) and Refractory to Prior Treatment with Glucocorticoids, an Immunomodulatory Agent, a Proteasome Inhibitor and an anti-CD38 mAbOpen
LCCC1241Complementary and Alternative medicine use at UNC clinicsOpen
LCCC1527Evaluation of the Chemotherapy Toxicity Risk Score for Treatment Decision in Elderly Patients with Advanced Solid CancerOpen
LCCC1715Detection and Analysis of MERTK in Cancer PatientsOpen
LCCC1726Randomized Placebo Controlled Trial of High Dose Intravenous Thiamine for the Prevention of Delirium in Allogeneic Hematopoietic Stem Cell TransplantationOpen
MM-398-01-01-02A Phase 1 Study in Patients Treated with MM-398 (Nanoliposomal Irinotecan, nal-IRI,) to Determine Tumor Drug Levels and to Evaluate the Feasibility of Ferumoxytol Magnetic Resonance Imaging to Measure Tumor Associated Macrophages and to Predict Patient Response to TreatmentOpen
NP39403NP39403-Open label, Multicenter, Dose escalation/expansion phase 1b study to evaluate safety, pharmacokinetics and activity of BET inhibitor R06870810, given as mono and combination therapy to patients with advanced Multiple MyelomaOpen
OT-15-001A Phase 3, Randomized, Open-Label Study To Evaluate the Efficacy and Safety of Eflornithine with Lomustine Compared to Lomustine Alone in Patients with Anaplastic Astrocytoma That Progress/Recur After Irradiation and Adjuvant Temozolomide Chemotherapy Open
PCRC-14-07Caregiver-­‐guided pain management training in palliative careOpen
RETROSHAVEComparison of surgical techniques for obtaining negative margins in patients with breast cancerOpen
RTOG1008A Randomized Phase II/III Study of Adjuvant Concurrent Radiation and Chemotherapy versus Radiation Alone in Resected High-Risk Malignant Salivary Gland Tumors Open
TBCRC038Diversity in the Tumor Genome and Microenvironment as Drivers of DCIS ProgressionOpen